These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37340065)

  • 1. A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma.
    Peng Y; Ren Y; Huang B; Tang J; Jv Y; Mao Q; Liu Y; Lei Y; Zhang Y
    Sci Rep; 2023 Jun; 13(1):9970. PubMed ID: 37340065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deep Learning for Noninvasive Assessment of H3 K27M Mutation Status in Diffuse Midline Gliomas Using MR Imaging.
    Li J; Zhang P; Qu L; Sun T; Duan Y; Wu M; Weng J; Li Z; Gong X; Liu X; Wang Y; Jia W; Su X; Yue Q; Li J; Zhang Z; Barkhof F; Huang RY; Chang K; Sair H; Ye C; Zhang L; Zhuo Z; Liu Y
    J Magn Reson Imaging; 2023 Sep; 58(3):850-861. PubMed ID: 36692205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma.
    Chai RC; Yan H; An SY; Pang B; Chen HY; Mu QH; Zhang KN; Zhang YW; Liu YQ; Liu X; Zhao Z; Jiang T; Wang YZ; Jia WQ
    Brain Pathol; 2023 Jul; 33(4):e13153. PubMed ID: 36751054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slow-Growing Thalamic Glioma with Histone H3 Lysine 27-to-Methionine Mutation: 3-Year Follow-Up Before Surgical Intervention.
    Chanchotisatien A; Pan J; Du Z; Qiu T; Yu J; Chu S
    World Neurosurg; 2019 Jul; 127():266-268. PubMed ID: 30981797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. H3 K27M-mutant diffuse midline gliomas in different anatomical locations.
    Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D
    Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
    Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
    Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
    J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children: A Retrospective Series of 164 Cases.
    Zheng L; Gong J; Yu T; Zou Y; Zhang M; Nie L; Chen X; Yue Q; Liu Y; Mao Q; Zhou Q; Chen N
    Am J Surg Pathol; 2022 Jun; 46(6):863-871. PubMed ID: 35416795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
    Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
    Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tectal Low-Grade Glioma with H3 K27M Mutation.
    Sumi K; Shijo K; Igarashi T; Yamamuro S; Sasano M; Oshima H; Ishige T; Honma T; Yagasaki H; Yoshino A
    World Neurosurg; 2020 Sep; 141():91-100. PubMed ID: 32505657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diffuse midline glioma].
    Saito R
    No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
    Dono A; Takayasu T; Ballester LY; Esquenazi Y
    J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of H3 K27M-mutant gliomas in adults.
    Meyronet D; Esteban-Mader M; Bonnet C; Joly MO; Uro-Coste E; Amiel-Benouaich A; Forest F; Rousselot-Denis C; Burel-Vandenbos F; Bourg V; Guyotat J; Fenouil T; Jouvet A; Honnorat J; Ducray F
    Neuro Oncol; 2017 Aug; 19(8):1127-1134. PubMed ID: 28201752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
    Donev K; Sundararajan V; Johnson D; Balan J; Chambers M; Paulson VA; Scherpelz KP; Abdullaev Z; Quezado M; Cimino PJ; Pratt D; Valerio E; Alves de Castro JV; Carraro DM; Torrezan GT; Wolff BM; Kulikowski LD; Costa FD; Aldape K; Ida CM
    J Neuropathol Exp Neurol; 2024 Apr; 83(5):357-364. PubMed ID: 38447592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter analysis of the prognostic value of histone H3 K27M mutation in adult high-grade spinal glioma.
    Akinduro OO; Garcia DP; Higgins DMO; Vivas-Buitrago T; Jentoft M; Solomon DA; Daniels DJ; Pennington Z; Sherman WJ; Delgardo M; Bydon M; Kalani MA; Zanazzi G; Tsankova N; Bendok BR; McCormick PC; Sciubba DM; Lo SL; Clarke JL; Abode-Iyamah K; Quiñones-Hinojosa A
    J Neurosurg Spine; 2021 Aug; 35(6):834-843. PubMed ID: 34416733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicoradiological characteristics of primary spinal cord H3 K27M-mutant diffuse midline glioma.
    Cheng L; Wang L; Yao Q; Ma L; Duan W; Guan J; Zhang C; Wang K; Liu Z; Wang X; Wang Z; Wu H; Chen Z; Jian F
    J Neurosurg Spine; 2022 Feb; 36(2):303-314. PubMed ID: 34560639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
    Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
    J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H3 K27M-mutant diffuse midline glioma with osseous metastases: A case report and a literature review.
    Al Sharie S; Talafha M; Abu Laban D; Al Awabdeh T; Al-Mousa A; Al-Masri N; Al-Hussaini M
    Clin Neuropathol; 2022; 41(6):263-270. PubMed ID: 35770519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.